By Muhammad Shabbor
Updated Date: September 24, 2026
Body weight can be an uncomfortable subject because it is often treated as a matter of appearance, discipline or willpower. Medically, however, obesity is considerably more complicated.
The World Health Organization describes obesity as a chronic disease involving excessive fat accumulation that can impair health. Genetics, biology, eating patterns, physical activity, the surrounding environment and access to healthy food can all influence a person's risk. (World Health Organization)
That matters because the health consequences can extend well beyond the number shown on a bathroom scale.
Obesity is associated with a higher risk of conditions including type 2 diabetes, cardiovascular disease, osteoarthritis, sleep-related breathing problems and certain cancers. The risk generally becomes greater as excess body fat increases, although health risk is not determined by weight alone. (World Health Organization)
Recent discussions among medical specialists in Pakistan have also highlighted the growing burden of obesity and its relationship with metabolic disease. At a metabolic-health forum attended by more than 1,100 doctors, specialists discussed obesity, diabetes, cardiovascular disease, kidney complications and newer treatment approaches.
The larger lesson is important: obesity deserves to be considered a health condition, not merely a cosmetic problem.
Why obesity can affect so many parts of the body
Excess body fat can influence multiple biological systems. It can affect blood pressure, blood sugar regulation, lipid metabolism, inflammation, joints and breathing during sleep.
This helps explain why obesity can appear alongside apparently unrelated problems.
The medical experts cited in the supplied report highlighted associations with conditions such as:
High blood pressure
Type 2 diabetes
Heart disease
Fatty liver disease
Sleep apnoea
Osteoarthritis
Depression
Kidney disease
WHO similarly identifies cardiovascular disease, type 2 diabetes, musculoskeletal disorders and several cancers among the important health conditions associated with overweight and obesity. (World Health Organization)
It is important, however, to interpret these relationships correctly. Saying obesity is associated with a disease does not mean every person with obesity will develop that disease, nor does it mean body weight is the only cause.
Age, genetics, smoking, diet, physical activity, existing medical conditions and many other factors can influence individual risk.
BMI is useful, but it does not tell the whole story
Body mass index, or BMI, is calculated using weight and height. For adults, WHO generally defines overweight as a BMI of 25 or higher and obesity as a BMI of 30 or higher. (World Health Organization)
BMI is useful because it provides a simple way to identify weight-related risk across large populations.
But it has limitations.
Two people can have the same BMI while having very different amounts and distributions of body fat, muscle mass and metabolic risk.
That is why clinicians may also consider:
Waist circumference
Blood pressure
Blood glucose or diabetes status
Cholesterol and other blood lipids
Liver health
Sleep problems
Mobility and joint symptoms
Existing cardiovascular or kidney disease
Previous attempts at weight management
The goal is not simply to make the number on a scale smaller. The more meaningful question is whether treatment can improve a person's overall health and reduce future complications.
Lifestyle remains an important part of treatment
Modern obesity treatment does not make healthy habits irrelevant.
Nutrition, physical activity, adequate sleep and sustainable behavioral changes remain important components of long-term weight management.
WHO recommends limiting sugar-sweetened beverages and energy-dense foods while emphasizing foods such as fruits, vegetables, legumes, whole grains and nuts. Regular physical activity is also part of healthy weight management. (World Health Organization)
But there is an important distinction between saying lifestyle matters and saying obesity can always be solved by "trying harder."
Obesity is influenced by biological and environmental factors. Some people experience substantial difficulty losing weight or maintaining weight loss even after making meaningful lifestyle changes.
That is one reason medical treatment can be appropriate for some people.
Where does semaglutide fit in?
Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists.
GLP-1 is a hormone involved in appetite regulation and glucose metabolism. Medicines that act on this pathway can influence appetite and food intake while also affecting blood sugar.
Clinical research has demonstrated that semaglutide can produce substantial weight loss in appropriately selected adults when used alongside lifestyle intervention.
In the STEP 1 randomized clinical trial, 1,961 adults with obesity or overweight plus a weight-related condition, but without diabetes, were followed for 68 weeks. Participants receiving weekly 2.4-mg semaglutide had an average weight reduction of 14.9%, compared with 2.4% with placebo, alongside lifestyle intervention. (New England Journal of Medicine)
That is significant evidence, but it should not be interpreted as meaning everyone taking semaglutide will lose the same amount of weight.
The trial had specific eligibility criteria, a defined treatment period and a particular study population. Real-world results can differ.
The research goes beyond weight loss
One of the more interesting developments in obesity medicine is the growing amount of research examining outcomes beyond body weight.
The SELECT trial studied adults with established cardiovascular disease who had overweight or obesity but did not have diabetes. Over a mean follow-up of about 40 months, the primary cardiovascular outcome occurred in 6.5% of participants receiving semaglutide compared with 8.0% receiving placebo. The reported hazard ratio was 0.80. (DOI)
In practical terms, the trial found fewer major cardiovascular events in the semaglutide group within this specific high-risk population.
However, that finding should not be generalized to every person with obesity. The participants had particular characteristics, including pre-existing cardiovascular disease and no diabetes.
Another major trial, FLOW, examined people with type 2 diabetes and chronic kidney disease. Among 3,533 randomized participants, the risk of the trial's primary kidney outcome was 24% lower with semaglutide than with placebo. (New England Journal of Medicine)
Again, context matters. FLOW was a trial involving people with type 2 diabetes and chronic kidney disease. Its results should not automatically be interpreted as proof that semaglutide prevents kidney disease in every person who takes it.
Why these medicines should not be treated as cosmetic shortcuts
The growing popularity of GLP-1 medicines has also created a risk of oversimplification.
Semaglutide is not simply a shortcut for someone who wants to lose a few pounds quickly.
Prescription weight-management medicines should be selected according to a person's health status, medical history, potential benefits, risks and treatment goals.
Clinical trials have also documented adverse effects. In the STEP 1 trial, gastrointestinal problems were among the notable adverse events, and gallbladder-related disorders were more common in the semaglutide group. (New England Journal of Medicine)
This is why obtaining medication through unverified sources or using someone else's prescription is a poor substitute for medical assessment.
A qualified clinician can determine whether medication is appropriate and monitor the person's response.
What about the claim that obesity is linked to 229 diseases?
The supplied report describes obesity as being associated with 229 diseases and provides several percentages for conditions observed among people with obesity.
Those figures are useful as part of the report's discussion, but they should not be interpreted as meaning that obesity inevitably causes 229 separate diseases in every individual.
A broader and better-established conclusion is that excess weight is associated with a wide range of chronic health problems.
WHO's current evidence summary includes cardiovascular disease, diabetes, musculoskeletal disorders and several cancers among the recognized health consequences associated with overweight and obesity. (World Health Organization)
For readers, this distinction matters. A large disease count can attract attention, but understanding which risks apply to you and what can be changed is much more useful than focusing on a single headline number.
What should someone concerned about their weight do?
The appropriate next step depends on the individual.
Instead of focusing exclusively on the scale, consider whether there are signs of metabolic or weight-related health problems such as:
Elevated blood pressure
Abnormal blood sugar
High cholesterol or triglycerides
Sleep problems or loud snoring
Reduced physical activity because of joint discomfort
Fatty liver disease
Increasing waist circumference
Difficulty maintaining weight loss despite sustained lifestyle efforts
A healthcare professional can assess these factors and determine whether lifestyle intervention alone is appropriate or whether additional treatment should be considered.
For some people, structured nutrition and physical-activity support may be enough. Others may benefit from medical treatment as part of a broader plan.
There is no single strategy that works identically for everyone.
A more useful way to think about weight management
Rather than asking only, "How much weight can I lose?", it may be more helpful to ask:
"What can I do to improve my health and maintain those improvements over time?"
That shift changes the conversation.
A modest and sustainable change in weight may be meaningful for one person, while another person with severe obesity and related complications may need more intensive treatment.
The right approach can depend on cardiovascular risk, diabetes status, kidney function, medications, age, mobility, eating patterns and previous treatment attempts.
This is also why treatment should not be based on BMI alone.
The bottom line
Obesity is a complex chronic health condition associated with a broad range of medical problems. It can increase the risk of diabetes, cardiovascular disease, joint disease, sleep-related breathing disorders and other complications. (World Health Organization)
Research has also changed the conversation about treatment. Semaglutide has demonstrated substantial average weight loss in clinical trials, while studies such as SELECT and FLOW have investigated cardiovascular and kidney outcomes in specific high-risk populations. (New England Journal of Medicine)
But these medicines are not appropriate for everyone, and the results of one clinical trial should not be treated as a guarantee for an individual.
The most useful approach is usually a comprehensive one: understand personal risk, build sustainable lifestyle habits, and discuss evidence-based treatment options with a qualified healthcare professional when needed.
For more general healthy-living information, readers can also explore Bright Social Life.
Medical Disclaimer
This article is for general educational purposes only and does not provide individualized medical advice. Health decisions, including whether prescription weight-management medication is appropriate, should be discussed with a qualified healthcare professional.
Sources
World Health Organization. Obesity and overweight. Updated December 8, 2025. (World Health Organization)
World Health Organization. Obesity: Health consequences of being overweight. March 1, 2024. (World Health Organization)
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. (New England Journal of Medicine)
Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023. (DOI)
Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. New England Journal of Medicine. 2024. (New England Journal of Medicine)
Suggested Internal Links
1. Anchor text: healthy living → Bright Social Life
.jpeg)
0 Comments